Symptomatic therapy in multiple sclerosis: Big pharma should do more

Abstract

Get full access to this article

View all access options for this article.

References

Thompson

Toosy

Ciccarelli

. Pharmacological management of symptoms in multiple sclerosis: Current approaches and future directions. Lancet Neurol 2010; 9: 1182–1199.

Hartung

Bourdette

Ahmed

. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology. Epub ahead of print 24 April 2015. pii: 10.1212/WNL 0000000000001608.

ClinicalTrials.gov, https://clinicaltrials.gov/ct2/results?term=multiple+sclerosis+&Search=Search (accessed 20 October 2014).

Goodman

Brown

Krupp

. Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet 2009; 373: 732–738.

Prugger

Berger

. Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: A review of 67 cases. Patient Relat Outcome Meas 2013; 4: 75–85.

Achiron

Givon

Magalashvili

. Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study. Mult Scler 2015; 21: 767–775.

Symptomatic therapy in multiple sclerosis: Big pharma should do more – commentary

Abstract

Get full access to this article

References